First Tracks Biotherapeutics, Inc. (TRAX)
| Market Cap | 1.12B+56.5% |
| Revenue (ttm) | n/a |
| Net Income | -160.30M |
| EPS | -4.71 |
| Shares Out | 35.73M |
| PE Ratio | n/a |
| Forward PE | -8.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 328,697 |
| Open | 33.31 |
| Previous Close | 30.59 |
| Day's Range | 30.11 - 33.31 |
| 52-Week Range | 14.72 - 49.91 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 70.00(+123.57%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About TRAX
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TRAX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TRAX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TRAX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TRAX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New TRAX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TRAX from public contracts
Source: USAspending.gov
TRAX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TRAX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score